Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 146 articles:
HTML format



Single Articles


    June 2024
  1. XU X, Wang W, He Y, Yao Y, et al
    Prognostic marker VPS72 could promote the malignant progression of prostate cancer.
    BMC Cancer. 2024;24:713.
    PubMed     Abstract available


  2. ZHU Q, Chen J, Liu H, Zhao J, et al
    The efficacy and safety of PARP inhibitors in mCRPC with HRR mutation in second-line treatment: a systematic review and bayesian network meta-analysis.
    BMC Cancer. 2024;24:706.
    PubMed     Abstract available


  3. CHENG TS, Noor U, Watts E, Pollak M, et al
    Circulating free insulin-like growth factor-I and prostate cancer: a case-control study nested in the European prospective investigation into cancer and nutrition.
    BMC Cancer. 2024;24:676.
    PubMed     Abstract available


    May 2024
  4. FU L, Zhang C, Wang Z, Tao W, et al
    Clinical application of serum tumor abnormal protein in prostate cancer patients.
    BMC Cancer. 2024;24:665.
    PubMed     Abstract available


  5. WANG B, Pan J, Zhang T, Ni X, et al
    Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen
    BMC Cancer. 2024;24:643.
    PubMed     Abstract available


  6. CUI F, Tang X, Man C, Fan Y, et al
    Prognostic value of 17-Gene genomic prostate score in patients with clinically localized prostate cancer: a meta-analysis.
    BMC Cancer. 2024;24:628.
    PubMed     Abstract available


  7. CHE B, Yuan S, Zhang H, Zhai J, et al
    Causal inference between pernicious anemia and cancers: a bidirectional two-sample mendelian randomization analysis.
    BMC Cancer. 2024;24:586.
    PubMed     Abstract available


  8. OBINATA D, Takayama K, Lawrence MG, Funakoshi D, et al
    Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
    BMC Cancer. 2024;24:554.
    PubMed     Abstract available


    April 2024
  9. IHEANACHO CO, Enechukwu OH
    Role of antihypertensive medicines in prostate cancer: a systematic review.
    BMC Cancer. 2024;24:542.
    PubMed     Abstract available


  10. YANG L, Ruan Y, Xu H
    HIST3H2A promotes the progression of prostate cancer through inhibiting cell necroptosis.
    BMC Cancer. 2024;24:544.
    PubMed     Abstract available


  11. COLETTA AM, Simon LH, Maslana K, Taylor S, et al
    Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial.
    BMC Cancer. 2024;24:493.
    PubMed     Abstract available


  12. LIU HE, Vuppalapaty M, Hoerner CR, Bergstrom CP, et al
    Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate c
    BMC Cancer. 2024;24:482.
    PubMed     Abstract available


  13. YOU X, Qiu J, Li Q, Zhang Q, et al
    Astragaloside IV-PESV inhibits prostate cancer tumor growth by restoring gut microbiota and microbial metabolic homeostasis via the AGE-RAGE pathway.
    BMC Cancer. 2024;24:472.
    PubMed     Abstract available


  14. DUAN L, Liu Z, Wan F, Dai B, et al
    Advantage of whole-mount histopathology in prostate cancer: current applications and future prospects.
    BMC Cancer. 2024;24:448.
    PubMed     Abstract available


  15. FREDMAN E, Icht O, Moore A, Bragilovski D, et al
    SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
    BMC Cancer. 2024;24:431.
    PubMed     Abstract available


  16. AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
    Correction: Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.
    BMC Cancer. 2024;24:419.
    PubMed    


    March 2024
  17. GUZMAN J, Weigelt K, Neumann A, Tripal P, et al
    NanoLuc Binary Technology as a methodological approach: an important new tool for studying the localization of androgen receptor and androgen receptor splice variant V7 homo and heterodimers.
    BMC Cancer. 2024;24:346.
    PubMed     Abstract available


  18. SHEN Z, Yao C, Bai Y, Wang Y, et al
    Transversal approach via a bladder neck and prostate combined longitudinal incision versus standard approach of robotic-assisted radical prostatectomy for localized prostate cancer: a retrospective analysis.
    BMC Cancer. 2024;24:313.
    PubMed     Abstract available


  19. CUI F, Qiu Y, Xu W, Zou C, et al
    Pretreatment prostate-specific antigen density as a predictor of biochemical recurrence in patients with prostate cancer: a meta-analysis.
    BMC Cancer. 2024;24:305.
    PubMed     Abstract available


  20. MIYAZAWA Y, Koike H, Oka D, Kawamura H, et al
    Comparison of sexual function after robot-assisted radical prostatectomy and carbon-ion radiotherapy for Japanese prostate cancer patients using propensity score matching.
    BMC Cancer. 2024;24:300.
    PubMed     Abstract available


  21. FU Q, Luo L, Hong R, Zhou H, et al
    Radiogenomic analysis of ultrasound phenotypic features coupled to proteomes predicts metastatic risk in primary prostate cancer.
    BMC Cancer. 2024;24:290.
    PubMed     Abstract available


  22. KHALIL MIM, Ashour A, Shaala RS, Allam RM, et al
    Effect of health belief model-based educational intervention on prostate cancer prevention; knowledge, practices, and intentions.
    BMC Cancer. 2024;24:289.
    PubMed     Abstract available


    February 2024
  23. HUANG H, Liu Y, Wen Z, Chen C, et al
    Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:261.
    PubMed     Abstract available


  24. CHEN J, Yu F, He G, Hao W, et al
    A nomogram based on peripheral lymphocyte for predicting 8-year survival in patients with prostate cancer: a single-center study using LASSO-cox regression.
    BMC Cancer. 2024;24:254.
    PubMed     Abstract available


  25. FARAMARZI S, Kiani B, Faramarzi S, Firouraghi N, et al
    Cancer patterns in Iran: a gender-specific spatial modelling of cancer incidence during 2014-2017.
    BMC Cancer. 2024;24:191.
    PubMed     Abstract available


    January 2024
  26. LING SW, van der Veldt AAM, Konijnenberg M, Segbers M, et al
    Evaluation of the tolerability and safety of [(225)Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.
    BMC Cancer. 2024;24:146.
    PubMed     Abstract available


  27. WANG J, Liu J, Yuan C, Yang B, et al
    Palmitic acid-activated GPRs/KLF7/CCL2 pathway is involved in the crosstalk between bone marrow adipocytes and prostate cancer.
    BMC Cancer. 2024;24:75.
    PubMed     Abstract available


  28. ENKE JS, Gross M, Grosser B, Sipos E, et al
    SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
    BMC Cancer. 2024;24:65.
    PubMed     Abstract available


  29. MULATI Y, Lai C, Luo J, Hu J, et al
    Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer.
    BMC Cancer. 2024;24:44.
    PubMed     Abstract available


  30. ZHAO S, Miao M, Wang Q, Zhao H, et al
    The current status of clinical trials on cancer and age disparities among the most common cancer trial participants.
    BMC Cancer. 2024;24:30.
    PubMed     Abstract available


  31. ZHOU X, Chai K, Zhu H, Luo C, et al
    The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target.
    BMC Cancer. 2024;24:8.
    PubMed     Abstract available


    December 2023
  32. DAI X, Shi X, Luo M, Li P, et al
    Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
    BMC Cancer. 2023;23:1241.
    PubMed     Abstract available


  33. GUAN A, Santiago-Rodriguez EJ, Chung BI, Shim JK, et al
    Patient and physician perspectives on treatments for low-risk prostate cancer: a qualitative study.
    BMC Cancer. 2023;23:1191.
    PubMed     Abstract available


    November 2023
  34. HASANI M, Alinia SP, Khazdouz M, Sobhani S, et al
    Oxidative balance score and risk of cancer: a systematic review and meta-analysis of observational studies.
    BMC Cancer. 2023;23:1143.
    PubMed     Abstract available


  35. CHEN Z, Zhang J, Jin D, Wei X, et al
    A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score.
    BMC Cancer. 2023;23:1138.
    PubMed     Abstract available


    October 2023
  36. HUANG L, Ma B, Zhang C, Shi J, et al
    Unveiling poly(rC)-binding protein 2 as the target protein for curcusone C against prostate cancer: mechanism validation through click chemistry-activity based proteomics profiling approach.
    BMC Cancer. 2023;23:957.
    PubMed     Abstract available


  37. AYOUB HM, Zamzam ML, Elsemary EE, Hassanin IM, et al
    Health-related quality of life of metastatic prostate cancer patients treated with prostate Radiotherapy.
    BMC Cancer. 2023;23:927.
    PubMed     Abstract available


    September 2023
  38. WOLFE S, Diven MA, Marciscano AE, Zhou XK, et al
    A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    BMC Cancer. 2023;23:923.
    PubMed     Abstract available


    August 2023
  39. MARCISCANO AE, Wolfe S, Zhou XK, Barbieri CE, et al
    Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER).
    BMC Cancer. 2023;23:781.
    PubMed     Abstract available


  40. WIESE D, DuBois TD, Sorice KA, Fang CY, et al
    Defining aggressive prostate cancer: a geospatial perspective.
    BMC Cancer. 2023;23:754.
    PubMed     Abstract available


  41. LUO J, Lai C, Xu X, Shi J, et al
    Mechanism of prognostic marker SPOCK3 affecting malignant progression of prostate cancer and construction of prognostic model.
    BMC Cancer. 2023;23:741.
    PubMed     Abstract available


    July 2023
  42. SHARMA D, McNabb E, Law N, Cumal A, et al
    Ultrasound-stimulated microbubbles enhancement of fractionated radiation for tumor treatment.
    BMC Cancer. 2023;23:693.
    PubMed     Abstract available


  43. ZIELSKE SP, Chen W, Ibrahim KG, Cackowski FC, et al
    SNHG1 opposes quiescence and promotes docetaxel sensitivity in prostate cancer.
    BMC Cancer. 2023;23:672.
    PubMed     Abstract available


  44. DENG S, Ding J, Wang H, Mao G, et al
    Deep learning-based radiomic nomograms for predicting Ki67 expression in prostate cancer.
    BMC Cancer. 2023;23:638.
    PubMed     Abstract available


  45. GUNTHER M, Hentschel L, Schuler M, Muller T, et al
    Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.
    BMC Cancer. 2023;23:629.
    PubMed     Abstract available


    June 2023
  46. AL-HAMMOURI T, Almeida-Magana R, Lawrence R, Duffy T, et al
    Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C-ProMeta-1).
    BMC Cancer. 2023;23:581.
    PubMed     Abstract available


  47. SCHIMMELPFENNIG C, Rade M, Fussel S, Loffler D, et al
    Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer.
    BMC Cancer. 2023;23:575.
    PubMed     Abstract available


  48. TSENG CS, Yang JH, Huang SW, Wang YJ, et al
    Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer.
    BMC Cancer. 2023;23:568.
    PubMed     Abstract available


  49. MATSUYAMA H, Matsubara N, Kazama H, Seto T, et al
    Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan.
    BMC Cancer. 2023;23:538.
    PubMed     Abstract available


  50. JAHNEN M, Bayer P, Meissner VH, Schiele S, et al
    Benefit finding in men affected by prostate cancer prior to and following radical prostatectomy - a cross-sectional study with a stratified sample.
    BMC Cancer. 2023;23:508.
    PubMed     Abstract available


    May 2023
  51. LI X, Yuan C, Yang B, Pang H, et al
    Caprylic Acid (FFA C8:0) promotes the progression of prostate cancer by up-regulating G protein-coupled receptor 84/ Kruppel-like factor 7.
    BMC Cancer. 2023;23:426.
    PubMed     Abstract available


  52. CAI X, Duan X, Tang T, Cui S, et al
    JMJD2A participates in cytoskeletal remodeling to regulate castration-resistant prostate cancer docetaxel resistance.
    BMC Cancer. 2023;23:423.
    PubMed     Abstract available


  53. HEESTERMAN BL, Aben KKH, de Jong IJ, Pos FJ, et al
    Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review.
    BMC Cancer. 2023;23:398.
    PubMed     Abstract available


  54. HYUN J, Ha MS, Oh SY, Tae JH, et al
    Urinary tract infection after radiation therapy or radical prostatectomy on the prognosis of patients with prostate cancer: a population-based study.
    BMC Cancer. 2023;23:395.
    PubMed     Abstract available


    April 2023
  55. MENDEZ LC, Dhar A, Laidley D, Moussa M, et al
    The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
    BMC Cancer. 2023;23:362.
    PubMed     Abstract available


  56. ASOWED M, Elander NO, Pettersson L, Ekholm M, et al
    Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer.
    BMC Cancer. 2023;23:309.
    PubMed     Abstract available


  57. BULAMU NB, Mpundu-Kaambwa C, O'Callaghan M, Kaambwa B, et al
    Responsiveness and construct validity of EPIC-26, AQoL-6D and SF-6D following treatment in prostate cancer.
    BMC Cancer. 2023;23:297.
    PubMed     Abstract available


    March 2023
  58. LIN Y, Zhang Y, Tuo Z, Gao L, et al
    ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.
    BMC Cancer. 2023;23:285.
    PubMed     Abstract available


  59. MA S, Chen Y, Quan P, Zhang J, et al
    NPAS2 promotes aerobic glycolysis and tumor growth in prostate cancer through HIF-1A signaling.
    BMC Cancer. 2023;23:280.
    PubMed     Abstract available


  60. VAN DER SAR ECA, Braat AJAT, van der Voort-van Zyp JRN, van der Veen BS, et al
    Tolerability of concurrent external beam radiotherapy and [(177)Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment naive patients, phase I study (PROQURE-I trial).
    BMC Cancer. 2023;23:268.
    PubMed     Abstract available


  61. KAWAHARA T, Saigusa Y, Yoneyama S, Kato M, et al
    Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide.
    BMC Cancer. 2023;23:214.
    PubMed     Abstract available


    January 2023
  62. CHENG X, Zeng Z, Yang H, Chen Y, et al
    Novel cuproptosis-related long non-coding RNA signature to predict prognosis in prostate carcinoma.
    BMC Cancer. 2023;23:105.
    PubMed     Abstract available


  63. ZHANG H, Huang D, Zhang Y, Wang X, et al
    Global burden of prostate cancer attributable to smoking among males in 204 countries and territories, 1990-2019.
    BMC Cancer. 2023;23:92.
    PubMed     Abstract available


  64. LIU Z, Zhu X, He J, Lu J, et al
    Metabolic syndrome and its components predict the biochemical recurrence and adverse pathological features of patients following radical prostatectomy: a propensity score matching study.
    BMC Cancer. 2023;23:50.
    PubMed     Abstract available


  65. TSUNEKI M, Abe M, Ichihara S, Kanavati F, et al
    Inference of core needle biopsy whole slide images requiring definitive therapy for prostate cancer.
    BMC Cancer. 2023;23:11.
    PubMed     Abstract available


    December 2022
  66. VLAMING M, Bleiker EMA, van Oort IM, Kiemeney LALM, et al
    Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study.
    BMC Cancer. 2022;22:1365.
    PubMed     Abstract available


  67. CUI X, Yu H, Yao J, Li J, et al
    ncRNA-mediated overexpression of ubiquitin-specific proteinase 13 contributes to the progression of prostate cancer via modulating AR signaling, DNA damage repair and immune infiltration.
    BMC Cancer. 2022;22:1350.
    PubMed     Abstract available


  68. DARRE T, Djiwa T, Kpatcha TM, Padja E, et al
    Prostate cancers in men under the age of 50: about a series in Togo, Sub-Saharan Africa.
    BMC Cancer. 2022;22:1341.
    PubMed     Abstract available


  69. GUAN J, Jiang X, Guo Y, Zhao W, et al
    Autophagy inhibition and reactive oxygen species elimination by acetyl-CoA acetyltransferase 1 through fused in sarcoma protein to promote prostate cancer.
    BMC Cancer. 2022;22:1313.
    PubMed     Abstract available


  70. RANS K, Charlien B, Filip A, Olivier H, et al
    SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
    BMC Cancer. 2022;22:1294.
    PubMed     Abstract available


  71. PAGADALA MS, Linscott JA, Talwar JV, Seibert TM, et al
    PRState: Incorporating genetic ancestry in prostate cancer risk scores for men of African ancestry.
    BMC Cancer. 2022;22:1289.
    PubMed     Abstract available


  72. ZHANG H, Du Y, Xin P, Man X, et al
    The LINC00852/miR-29a-3p/JARID2 axis regulates the proliferation and invasion of prostate cancer cell.
    BMC Cancer. 2022;22:1269.
    PubMed     Abstract available


    November 2022
  73. MIYOSHI Y, Kawahara T, Uemura H
    A high serum dehydroepiandrosterone concentration is a predictor of candidates for active surveillance in men with serum prostate-specific antigen < 10 ng/mL.
    BMC Cancer. 2022;22:1169.
    PubMed     Abstract available


  74. HUANG Q, Zi H, Luo L, Li X, et al
    Secular trends of morbidity and mortality of prostate, bladder, and kidney cancers in China, 1990 to 2019 and their predictions to 2030.
    BMC Cancer. 2022;22:1164.
    PubMed     Abstract available


  75. KOPCALIC K, Matic IZ, Besu I, Stankovic V, et al
    Circulating levels of IL-6 and TGF-beta1 in patients with prostate cancer undergoing radiotherapy: associations with acute radiotoxicity and fatigue symptoms.
    BMC Cancer. 2022;22:1167.
    PubMed     Abstract available


  76. ZENG Z, He W, Jiang Y, Jiang H, et al
    MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer.
    BMC Cancer. 2022;22:1162.
    PubMed     Abstract available


    October 2022
  77. SADOVSKA L, Zayakin P, Bajo-Santos C, Endzelins E, et al
    Effects of urinary extracellular vesicles from prostate cancer patients on the transcriptomes of cancer-associated and normal fibroblasts.
    BMC Cancer. 2022;22:1055.
    PubMed     Abstract available


    September 2022
  78. OLOKPA E, Mandape SN, Pratap S, Stewart MV, et al
    Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells.
    BMC Cancer. 2022;22:1025.
    PubMed     Abstract available


    August 2022
  79. WANG J, Huang J, Guo Y, Fu Y, et al
    Identification and functional analysis of LncRNA-XIST ceRNA network in prostate cancer.
    BMC Cancer. 2022;22:935.
    PubMed     Abstract available


  80. LOPHATANANON A, Byrne MHV, Barrett T, Warren A, et al
    Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population.
    BMC Cancer. 2022;22:878.
    PubMed     Abstract available


  81. O'NEILL C, Donnelly DW, Harbinson M, Kearney T, et al
    Survival of cancer patients with pre-existing heart disease.
    BMC Cancer. 2022;22:847.
    PubMed     Abstract available


    July 2022
  82. GNAGNARELLA P, Marvaso G, Jereczek-Fossa BA, de Cobelli O, et al
    Life style and interaction with microbiota in prostate cancer patients undergoing radiotherapy: study protocol for a randomized controlled trial.
    BMC Cancer. 2022;22:794.
    PubMed     Abstract available


  83. LIU C, Gao Y, Ni J, Chen S, et al
    The ferroptosis-related long non-coding RNAs signature predicts biochemical recurrence and immune cell infiltration in prostate cancer.
    BMC Cancer. 2022;22:788.
    PubMed     Abstract available


    June 2022
  84. LI Q, Yan M, Wang C, Wang K, et al
    CKAP2L, a crucial target of miR-326, promotes prostate cancer progression.
    BMC Cancer. 2022;22:666.
    PubMed     Abstract available


  85. ABERA SF, Bedir A, Glowka A, Vordermark D, et al
    Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data.
    BMC Cancer. 2022;22:624.
    PubMed     Abstract available


    May 2022
  86. NOWLAN B, Williams ED, Doran MR
    Direct bone marrow injection of human bone marrow-derived stromal cells into mouse femurs results in greater prostate cancer PC-3 cell proliferation, but not specifically proliferation within the injected femurs.
    BMC Cancer. 2022;22:554.
    PubMed     Abstract available


  87. DADHANIA V, Gonzalez D, Yousif M, Cheng J, et al
    Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.
    BMC Cancer. 2022;22:494.
    PubMed     Abstract available


  88. JANSSEN J, Staal FHE, Brouwer CL, Langendijk JA, et al
    Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy (ADOPT): study protocol for a randomised phase III trial.
    BMC Cancer. 2022;22:482.
    PubMed     Abstract available


    April 2022
  89. ANDERSON AB, Grazal C, Wedin R, Kuo C, et al
    Machine learning algorithms to estimate 10-Year survival in patients with bone metastases due to prostate cancer: toward a disease-specific survival estimation tool.
    BMC Cancer. 2022;22:476.
    PubMed     Abstract available


  90. KAZAMA H, Kawaguchi O, Seto T, Suzuki K, et al
    Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer.
    BMC Cancer. 2022;22:470.
    PubMed     Abstract available


  91. STAAL FHE, Janssen J, Brouwer CL, Langendijk JA, et al
    Phase III randomised controlled trial on PSMA PET/CT guided hypofractionated salvage prostate bed radiotherapy of biochemical failure after radical prostatectomy for prostate cancer (PERYTON-trial): study protocol.
    BMC Cancer. 2022;22:416.
    PubMed     Abstract available


  92. MYINT ZW, El Khouli R, Lemieux B, Yan D, et al
    A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
    BMC Cancer. 2022;22:415.
    PubMed     Abstract available


  93. MANUELLI V, Cahill F, Wylie H, Gillett C, et al
    Invadopodia play a role in prostate cancer progression.
    BMC Cancer. 2022;22:386.
    PubMed     Abstract available


  94. POTESKA R, Rahbar K, Semjonow A, Schrader AJ, et al
    The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide.
    BMC Cancer. 2022;22:375.
    PubMed     Abstract available


  95. CUADRAS M, Planas J, Celma A, Regis L, et al
    Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review.
    BMC Cancer. 2022;22:357.
    PubMed     Abstract available


    March 2022
  96. HE M, Wang L, Wang H, Liu F, et al
    A preliminary study on the diagnostic value of PSADR, DPC and TSRP in the distinction of prostatitis and prostate cancer.
    BMC Cancer. 2022;22:348.
    PubMed     Abstract available


  97. SPOHN SKB, Adebahr S, Huber M, Jenkner C, et al
    Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients.
    BMC Cancer. 2022;22:337.
    PubMed     Abstract available


  98. QASIM M, Puigjaner D, Herrero J, Lopez JM, et al
    Biomechanical modelling of the pelvic system: improving the accuracy of the location of neoplasms in MRI-TRUS fusion prostate biopsy.
    BMC Cancer. 2022;22:338.
    PubMed     Abstract available


  99. HUSSAIN A, Jiang S, Varghese D, Appukkuttan S, et al
    Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States.
    BMC Cancer. 2022;22:304.
    PubMed     Abstract available


  100. KOO K, Papa N, Evans M, Jefford M, et al
    Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography.
    BMC Cancer. 2022;22:283.
    PubMed     Abstract available


  101. MENARD C, Young S, Zukotynski K, Hamilton RJ, et al
    PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial.
    BMC Cancer. 2022;22:251.
    PubMed     Abstract available


  102. ZHAO Y, Tao Z, Li L, Zheng J, et al
    Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
    BMC Cancer. 2022;22:239.
    PubMed     Abstract available


    February 2022
  103. LIU W, Zhu Y, Ye L, Zhu Y, et al
    Correction: Establishment of an orthotopic prostate cancer xenograft mouse model using microscope-guided orthotopic injection of LNCaP cells into the dorsal lobe of the mouse prostate.
    BMC Cancer. 2022;22:200.
    PubMed    


  104. YANG X, Chen H, Xu D, Chen X, et al
    Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a mul
    BMC Cancer. 2022;22:177.
    PubMed     Abstract available


  105. LIU W, Zhu Y, Ye L, Zhu Y, et al
    Establishment of an orthotopic prostate cancer xenograft mouse model using microscope-guided orthotopic injection of LNCaP cells into the dorsal lobe of the mouse prostate.
    BMC Cancer. 2022;22:173.
    PubMed     Abstract available


    January 2022
  106. GRAYLING MJ, McMenamin M, Chandler R, Heer R, et al
    Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials.
    BMC Cancer. 2022;22:111.
    PubMed     Abstract available


  107. SHAH S, Beckmann K, Van Hemelrijck M, Challacombe B, et al
    Correction to: Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
    BMC Cancer. 2022;22:97.
    PubMed    


  108. COUDERC AL, Villani P, Berbis J, Nouguerede E, et al
    HoSAGE: sarcopenia in older patient with intermediate / high-risk prostate cancer, prevalence and incidence after androgen deprivation therapy: study protocol for a cohort trial.
    BMC Cancer. 2022;22:78.
    PubMed     Abstract available


    December 2021
  109. LIU AY
    The opposing action of stromal cell proenkephalin and stem cell transcription factors in prostate cancer differentiation.
    BMC Cancer. 2021;21:1335.
    PubMed     Abstract available


  110. RASOULI MA, Moradi G, Zareie B, Sofimajidpour H, et al
    Overall survival and prognostic factors prostate cancer in Kurdistan Province-Iran: a population-based study (2011-2018).
    BMC Cancer. 2021;21:1314.
    PubMed     Abstract available


  111. SCHNEPP PM, Ahmed A, Escara-Wilke J, Dai J, et al
    Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer.
    BMC Cancer. 2021;21:1316.
    PubMed     Abstract available


    November 2021
  112. BYEON S, Kim H, Jeon HG, Seo SI, et al
    A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naive prostate cancer.
    BMC Cancer. 2021;21:1281.
    PubMed     Abstract available


  113. MAZZONI AS, Brooke HL, Berntsen S, Nordin K, et al
    Effect of self-regulatory behaviour change techniques and predictors of physical activity maintenance in cancer survivors: a 12-month follow-up of the Phys-Can RCT.
    BMC Cancer. 2021;21:1272.
    PubMed     Abstract available


  114. LIN E, Garmo H, Van Hemelrijck M, Adolfsson J, et al
    Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study.
    BMC Cancer. 2021;21:1259.
    PubMed     Abstract available


    October 2021
  115. SHEN C, Tung C, Chao C, Jou Y, et al
    The differential presence of human polyomaviruses, JCPyV and BKPyV, in prostate cancer and benign prostate hypertrophy tissues.
    BMC Cancer. 2021;21:1141.
    PubMed     Abstract available


  116. LI F, Zhao Z, Zhang Z, Zhang Y, et al
    Tryptophan metabolism induced by TDO2 promotes prostatic cancer chemotherapy resistance in a AhR/c-Myc dependent manner.
    BMC Cancer. 2021;21:1112.
    PubMed     Abstract available


  117. ZHANG Y, Liu Q, Wei W, Zhang G, et al
    Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/beta-catenin signal pathway in prostate cancer cells.
    BMC Cancer. 2021;21:1101.
    PubMed     Abstract available


  118. WEINER F, Schille JT, Koczan D, Wu XF, et al
    Novel chemotherapeutic agent FX-9 activates NF-kappaB signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line.
    BMC Cancer. 2021;21:1088.
    PubMed     Abstract available


  119. GAMPER EM, Musoro JZ, Coens C, Stelmes JJ, et al
    Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials.
    BMC Cancer. 2021;21:1083.
    PubMed     Abstract available


    September 2021
  120. RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
    Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
    BMC Cancer. 2021;21:1055.
    PubMed     Abstract available


  121. JAHNEN M, Mynzak E, Meissner VH, Schiele S, et al
    Diversity of cancer-related identities in long-term prostate cancer survivors after radical prostatectomy.
    BMC Cancer. 2021;21:1041.
    PubMed     Abstract available


  122. SHIINA M, Hashimoto Y, Kulkarni P, Dasgupta P, et al
    Role of miR-182/PDCD4 axis in aggressive behavior of prostate cancer in the African Americans.
    BMC Cancer. 2021;21:1028.
    PubMed     Abstract available


  123. LI Q, Xiao M, Shi Y, Hu J, et al
    eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
    BMC Cancer. 2021;21:1022.
    PubMed     Abstract available


  124. SHARMA D, Osapoetra LO, Faltyn M, Giles A, et al
    In vivo assessment of prostate cancer response using quantitative ultrasound characterization of ultrasonic scattering properties.
    BMC Cancer. 2021;21:991.
    PubMed     Abstract available


    August 2021
  125. ANDKHOIE M, Szafron M
    Geographic disparities in Saskatchewan prostate cancer incidence and its association with physician density: analysis using Bayesian models.
    BMC Cancer. 2021;21:948.
    PubMed     Abstract available


  126. NAHAND JS, Khanaliha K, Mirzaei H, Moghoofei M, et al
    Possible role of HPV/EBV coinfection in anoikis resistance and development in prostate cancer.
    BMC Cancer. 2021;21:926.
    PubMed     Abstract available


  127. YANG Z, Ni Y, Zhao D, Zhang Y, et al
    Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone.
    BMC Cancer. 2021;21:919.
    PubMed     Abstract available


  128. ORTIZ-OTERO N, Marshall JR, Glenn A, Matloubieh J, et al
    TRAIL-coated leukocytes to kill circulating tumor cells in the flowing blood from prostate cancer patients.
    BMC Cancer. 2021;21:898.
    PubMed     Abstract available


    July 2021
  129. IMADA EL, Sanchez DF, Dinalankara W, Vidotto T, et al
    Transcriptional landscape of PTEN loss in primary prostate cancer.
    BMC Cancer. 2021;21:856.
    PubMed     Abstract available


  130. MANGIOLA S, McCoy P, Modrak M, Souza-Fonseca-Guimaraes F, et al
    Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression.
    BMC Cancer. 2021;21:846.
    PubMed     Abstract available


    June 2021
  131. CHONG W, Zhang Z, Luo R, Gu J, et al
    Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.
    BMC Cancer. 2021;21:655.
    PubMed     Abstract available


    May 2021
  132. ELLIS SD, Hwang S, Morrow E, Kimminau KS, et al
    Perceived barriers to the adoption of active surveillance in low-risk prostate cancer: a qualitative analysis of community and academic urologists.
    BMC Cancer. 2021;21:649.
    PubMed     Abstract available


  133. OKAMOTO T, Noro D, Hatakeyama S, Narita S, et al
    Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study.
    BMC Cancer. 2021;21:605.
    PubMed     Abstract available


  134. SHAH S, Beckmann K, Van Hemelrijck M, Challacombe B, et al
    Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
    BMC Cancer. 2021;21:573.
    PubMed     Abstract available


  135. MA TM, Lamb JM, Casado M, Wang X, et al
    Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    BMC Cancer. 2021;21:538.
    PubMed     Abstract available


  136. CALAIS J, Zhu S, Hirmas N, Eiber M, et al
    Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.
    BMC Cancer. 2021;21:512.
    PubMed     Abstract available


  137. AHETO JMK, Utuama OA, Dagne GA
    Geospatial analysis, web-based mapping and determinants of prostate cancer incidence in Georgia counties: evidence from the 2012-2016 SEER data.
    BMC Cancer. 2021;21:508.
    PubMed     Abstract available


  138. TAKESHIMA Y, Yamada Y, Teshima T, Fujimura T, et al
    Clinical significance and risk factors of International Society of Urological Pathology (ISUP) grade upgrading in prostate cancer patients undergoing robot-assisted radical prostatectomy.
    BMC Cancer. 2021;21:501.
    PubMed     Abstract available


    April 2021
  139. LEE J, Yang SW, Jin L, Lee CL, et al
    Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels?
    BMC Cancer. 2021;21:472.
    PubMed     Abstract available


  140. WATANABE D, Kimura T, Watanabe K, Takano H, et al
    Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
    BMC Cancer. 2021;21:422.
    PubMed     Abstract available


  141. LIN H, Liu Q, Zeng X, Yu W, et al
    Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study.
    BMC Cancer. 2021;21:399.
    PubMed     Abstract available


  142. NGUYEN HTN, Xue H, Firlej V, Ponty Y, et al
    Reference-free transcriptome signatures for prostate cancer prognosis.
    BMC Cancer. 2021;21:394.
    PubMed     Abstract available


    March 2021
  143. WIND A, Hartman ED, Van Eekeren RRJP, Wijn RPWF, et al
    Validating a generic cancer consumer quality index in eight European countries, patient reported experiences and the influence of cultural differences.
    BMC Cancer. 2021;21:231.
    PubMed     Abstract available


    February 2021
  144. THUREAU S, Marchesi V, Vieillard MH, Perrier L, et al
    Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase II
    BMC Cancer. 2021;21:117.
    PubMed     Abstract available


    December 2020
  145. DODLA P, Bhoopalan V, Khoo SK, Miranti C, et al
    Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82.
    BMC Cancer. 2020;20:1211.
    PubMed     Abstract available


    November 2020
  146. HERNANDEZ VARGAS JA, Ramirez Barbosa PX, Gil Quijano AM, Valbuena AM, et al
    Patterns of breast, prostate and cervical cancer incidence and mortality in Colombia: an administrative registry data analysis.
    BMC Cancer. 2020;20:1097.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.